Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2013

View Archived Issues

Jazz Pharmaceuticals presents company outlook

Discovery of novel dual NK1 receptor antagonist/SERT inhibitor for the treatment of depression

International Stem Cell tests its hpSC-derived hepatocytes in vivo

Bosutinib receives positive CHMP opinion for conditional marketing authorization

CHMP recommends approval of Jetrea in Europe for vitreomacular traction

Novel antibacterials created by Kyorin and Merck & Co.

YH-GKA identified as a novel glucokinase activator for treating diabetes

New HDAC6 inhibitors designed at U.S. institutes

Researchers design a gene knockout mouse using TALEN-mediated mutagenesis in zygotes

State University of New Jersey patents novel RNA polymerase bipartite inhibitors

Research at Myrexis yields new NAmPRTase inhibitors

Research at Roche and Genentech disclose novel PC9-binding peptides

University of Pittsburgh designs novel H1N1 influenza vaccines

Serina Therapeutics partners with AstraZeneca

Cancer Research UK and AstraZeneca begin clinical development of AZD-0424

Hexal presents new prodrugs of cilazapril

FDA approves Botox for overactive bladder

EMA confirms recommendation to suspend nicotinic acid/laropiprant

Roche presents new HCV therapeutics

Recordati completes acquisition of certain Lundbeck products

Phase II trial of ponatinib in squamous cell lung cancer begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...